If you also need proven heart protection and you have type 2 diabetes with established cardiovascular disease, semaglutide (Ozempic) has an FDA indication for this benefit
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes and obesity
Shortages of the drug, along with semaglutide the active ingredient in Ozempic and Wegovy have fueled unprecedented demand for compounding pharmacies to make their own versions of the medicines, which patients say are often cheaper and easier to come by than the brand-name versions
GLP-1 Activity GLP-1 receptor activation can help reduce appetite, slow gastric emptying, support insulin response, and improve blood sugar regulation
Europe represents the second-largest GLP-1 market region with 19.4% revenue share and 13.8% CAGR
Always talk to your doctor about your health risks and needs before you start or stop any drug
